How MSI and TMB Factor into Current Biomarker Testing Panels

Video Library - 2018 ASCO Insights, Video
Sanjiv Agarwala, MD
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Related Items
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Who Should Consider Genetic Testing?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Last modified: July 25, 2018